UniQure has developed the first and currently only gene therapy product to receive approval in the European Union. The product, Glybera, was approved in October 2012 for the treatment of a subset of patients with lipoprotein lipase deficiency.
The initial public offering gives UniQure an initial market cap of approximately $286m. They trade on the Nasdaq under ticker symbol QURE. Jefferies and Leerink Partners served as lead underwriters and have a 30-day option to buy an additional 810,000 shares of common stock.
In 2013 Chiesi Farmaceutici backed the commercialisation of Glybera with €31.1m (then worth $39.8m) in equity and collaboration financing.
Existing shareholders include secondaries investor Coller Capital (44.5% pre-IPO stake), Forbion (35.6%), Gilde Healthcare (13.5%), Chiesi Farmaceutici (9.1%) and Advent Venture Partners (6.2%).